Advertisement

Advertisement
Genomics/Genetics
Breast Cancer
Gynecologic Cancers

USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer

As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended risk assessment and, if indicated, genetic counseling...

Bladder Cancer

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al...

Pancreatic Cancer
Prostate Cancer

USPSTF Recommendation Against Pancreatic Cancer Screening in Asymptomatic Adults

This week on The ASCO Post Podcast, we review the U.S. Preventive Services Task Force (USPSTF) recommendation against screening for pancreatic cancer in adults with no symptoms...


Advertisement
Genomics/Genetics
Issues in Oncology

How Technology Is Transforming the Assessment of Inherited Cancer Risk

ASCO published its first statement on genetic testing and its impact on oncology practice over 2 decades ago. Since then, ASCO has revised the statement three times...

Global Cancer Care

WHO Releases Report on the Global Tobacco Epidemic

On July 26, 2019, the World Health Organization (WHO) issued a new report, “Global Tobacco Epidemic 2019,” to discuss national efforts being made to implement...

Advertisement




More Top Stories

Skin Cancer
Immunotherapy

Ahmad A. Tarhini, MD, PhD, on High-Risk Melanoma: Adjuvant Ipilimumab vs High-Dose Interferon-α2b

Sylvester Comprehensive Cancer Center Earns NCI Designation

Sylvester Comprehensive Cancer Center, part of the University of Miami Leonard M. Miller School of Medicine, has been named a National Cancer Institute (NCI)-designated cancer center. The NCI designation recognizes Sylvester as among the top cancer centers in the United States. Sylvester joins a...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Solid Tumors
Immunotherapy

Sarah Abou Alaiwi, MD, and Toni K. Choueiri, MD, on Checkpoint Inhibitors: Overall Survival and Polybromo-Associated Mutations

Hematologic Malignancies

FDA Approves Rituximab Biosimilar

On July 24, the U.S. Food and Drug Administration (FDA) approved rituximab-pvvr -(Ruxience), a biosimilar to rituximab (Rituxan), for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis and microscopic polyangi-itis....

Breast Cancer
Genomics/Genetics

How Laura J. van ’t Veer, PhD, Became an Expert in Genetic Testing for Breast Cancer

Breast cancer researcher and innovator Laura J. van ’t Veer, PhD, was born and reared in Amsterdam in 1957. “During high school, I had a wonderful biology teacher who was going through his own biology studies at the University of Amsterdam, and he was bringing that university-level education into ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Leukemia
Lymphoma
Immunotherapy

William G. Wierda, MD, PhD, on Immunotherapy for Relapsed/Refractory CLL/SLL: Results From TRANSCEND CLL 004

Broad Institute Launches Cancer Diagnostics Center

The Broad Institute of MIT and Harvard recently announced a new $15 million commitment by Louis V. Gerstner, Jr, former Corporate Executive Officer and Chairman of the Board of IBM Corporation, and Current Chairman of the Board of Directors of the Broad Institute, to create the Gerstner Center for...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...